DÄ internationalArchive24/2010What About Existing Databases?
LNSLNS

We agree that research into and treatment optimization of multidrug resistant tuberculosis can be successfully undertaken only by way of a joint effort.

We were surprised that the review article did not mention representative data collections of patients with MDR-TB and XDR-TB in Germany. From 2004 to 2006, the Tuberculosis Network European Trials-group (TBNET) systematically collected data from patients with MDR-TB and XDR-TB in 27 hospitals and evaluated the therapeutic successes (1). TBNET is a European alliance of doctors in clinical practice as well as scientists; the group’s remit is TB research. The network receives funding from the European Union and is closely linked to the European Respiratory Society. In a study of 4557 TB patients, 177 patients were found to have MDR-TB and 7, XDR-TB. This amounts to two thirds of all patients known to have MDR-TB or XDR-TB in Germany. The mean inpatient stay for XDR-TB is 202 days, and for MDR-TB, 123 days. The expensive inpatient care, comprehensive testing for antibiotic resistance, and the availability of all required medications have yielded excellent treatment results in 89% or 80% of the cases that were subsequently documented. In 2010, TBNET has established a database to capture MDR-TB and XDR-TB in Europe, with the aim to provide a comprehensive prospective and retrospective analysis of MDR-TB and XDR-TB. We are asking our colleagues who treat patients with MDR-TB and XDR-TB to join in the concerted effort and participate in the database project, so as to make a contribution to research into this intractable disease (information at www.tb-net.org or from gguenther@fz-borstel.de).

DOI: 10.3238/arztebl.2010.0435c

Dr. med. Christian Herzmann, MRCP(UK)

Dr. med. Gunar Günther

Dr. med Barbara Eker

Prof. Dr. med. Christoph Lange

Forschungszentrum Borstel

Parkallee 35

23845 Borstel, Germany

cherzmann@fz-borstel.de

Prof. Dr. med. Giovanni Battista Migliori

Fondazione S. Maugeri

Care and Research Institute

Via Roncaccio 16

21049 Tradate, Italia

1.
Eker B, Ortmann J, Migliori GB, et al. for the TBNET: Multi-drug resistant and extensively drug resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14(11):1700–6. MEDLINE
2.
Loddenkemper R, Hauer B: Drug resistant tuberculosis—A world wide epidemic poses a new challenge [Resistente Tuberkulose – Große Herausforderung durch eine Weltepidemie]. Dtsch Arztebl Int 2010; 107(1–2): 10–9. VOLLTEXT
1.Eker B, Ortmann J, Migliori GB, et al. for the TBNET: Multi-drug resistant and extensively drug resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14(11):1700–6. MEDLINE
2.Loddenkemper R, Hauer B: Drug resistant tuberculosis—A world wide epidemic poses a new challenge [Resistente Tuberkulose – Große Herausforderung durch eine Weltepidemie]. Dtsch Arztebl Int 2010; 107(1–2): 10–9. VOLLTEXT